Nanoform Finland Oyj

Equities

NANOFH

FI4000330972

Biotechnology & Medical Research

Market Closed - Nasdaq Helsinki Other stock markets 11:29:40 2024-04-18 am EDT			5-day change	1st Jan Change
2.465 ^EUR	-2.38%		-7.85%	+55.52%

Apr. 11	Nanoform Finland to Deliver Nanomedicine Technology to Japan	MT
Apr. 11	Nanoform Enters Exclusive Partnership with CBC to Bring Best-In-Class Nanomedicine Technology to Japan	CI

Nanoform Finland Oyj Provides Earnings Guidance or the Year 2025

February 22, 2022 at 01:10 am EST

Nanoform Finland Oyj provided earnings guidance or the year 2025. The company revenues expected to continue to grow rapidly this lays a solid foundation for a journey towards first becoming EBITDA, then EBIT, and finally cashflow positive by 2025.

Latest news about Nanoform Finland Oyj

Nanoform Finland to Deliver Nanomedicine Technology to Japan	Apr. 11	MT
Nanoform Enters Exclusive Partnership with CBC to Bring Best-In-Class Nanomedicine Technology to Japan	Apr. 11	CI
Nanoform Teams Up with PlusVitech to Repurpose Anti-Nausea Drug for Lung Cancer Treatment	Apr. 09	MT
Nanoform Finland plc and Plusvitech Partner to Repurpose Aprepitant as A Treatment for Lung Cancer	Apr. 09	CI
Nanoform Finland Oyj Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
Nanoform Finland Oyj Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 29	CI
Transcript : Nanoform Finland Oyj, 2023 Earnings Call, Feb 29, 2024	Feb. 29
Nanoform Finland plc Receives Positive Results from its Own Pre- Clinical, In-Vivo Study of a Nanocrystalline-Enabled Apalutamide Oral Formulation	Feb. 29	CI
Transcript : Nanoform Finland Oyj - Special Call	Jan. 26
Nanoform Announces Important Milestone with Promising Clinical Results for Patient-Centric Nanotechnology-Enhanced Enzalutamide	Jan. 26	CI
Nanoform Finland Starts Clinical Trial for Nanocrystalline Alternative of Prostrate Cancer Drug	Jan. 05	MT
Nanoform Finland plc Commences Relative Bioavailability Study of Nanotechnology-Enhanced Enzalutamide	Jan. 05	CI
Transcript : Nanoform Finland Oyj, Q3 2023 Earnings Call, Nov 22, 2023	Nov. 22
Nanoform Finland Oyj Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 22	CI
Nanoform Finland Signs Licensing Deal for AI Technology with AstraZeneca	23-10-23	MT
Nanoform Grant Global STARMAP[®] AI License to AstraZeneca	23-10-23	CI
Transcript : Nanoform Finland Oyj, Q2 2023 Earnings Call, Aug 24, 2023	23-08-24
Nanoform Finland Oyj Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-24	CI
Finland’s Nanoform, Celanese to Advance Partnership in Nanoparticle-enabled Drug Delivery Study	23-06-15	MT
Nanoform and Celanese Demonstrate Enhanced Drug Delivery Through the Power of Smaller Implants	23-06-15	CI
Transcript : Nanoform Finland Oyj, Q1 2023 Earnings Call, May 25, 2023	23-05-25
Nanoform Finland Oyj Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-25	CI
Finnish Medicines Agency Renews Nanoform's GMP License and Nanoform Starts Clinical API Manufacturing of Blockbuster Medicine Candidate	23-05-09	CI
Nanoform Finland plc Announces Board Appointments	23-04-12	CI
Transcript : Nanoform Finland Oyj, Q4 2022 Earnings Call, Feb 28, 2023	23-02-28

Chart Nanoform Finland Oyj

Duration

Period

More charts

Company Profile

Nanoform Finland Oyj is a Finland-based company that operates in the global pharmaceutical industry. The Company is an early-stage growth Company that develops various nanoforming technologies for application in the field of nanomedicine. Nanoform Finland Oyj's business is to offer expert services in nanotechnology as well as drug particle engineering for global pharma and biotech industry. Nanoform Finland Oyj is the Parent Company of the Nanoform Group, and it has one subsidiary - Nanoform USA Inc. The Group production, research and development functions operate in Finland. The Group's strategy is to sell nanotechnological services widely to minimize the dependence from single customers or projects.

Sector

Biotechnology & Medical Research

Calendar

2024-05-20 - Global DDF Summit

More about the company

Income Statement Evolution

More financial data

Ratings for Nanoform Finland Oyj

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.465 EUR

Average target price

4.4 EUR

Spread / Average Target

+78.50%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
NANOFORM FINLAND OYJ	+55.52%	206M
IQVIA HOLDINGS INC.	-1.82%	41.35B
LONZA GROUP AG	+44.25%	40.38B
MODERNA, INC.	+2.56%	39.05B
CELLTRION, INC.	-12.11%	26.67B
ICON PUBLIC LIMITED COMPANY	+3.09%	24.07B
ALNYLAM PHARMACEUTICALS, INC.	-24.16%	18.36B
MEDPACE HOLDINGS, INC.	+22.12%	11.6B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.74%	11.68B
UNITED THERAPEUTICS CORPORATION	+7.75%	11.15B

Other Biotechnology & Medical Research